Evaluating the Safety and Efficacy of Intraoperative Cell Salvage in Cesarean Delivery for Placenta Accreta Spectrum: A Propensity Score-Matched Retrospective Study

评估剖宫产术中自体血液回收治疗胎盘植入谱系疾病的安全性和有效性:一项倾向评分匹配的回顾性研究

阅读:1

Abstract

PURPOSE: The Placenta Accreta Spectrum (PAS) poses a significant obstetric challenge, often leading to life-threatening hemorrhage during delivery. Intraoperative Cell Salvage (IOCS) is a promising but insufficiently studied blood conservation approach. PATIENTS AND METHODS: This retrospective cohort investigation employed propensity score matching to analyze 102 PAS cases diagnosed through combined preoperative MRI and ultrasound at a tertiary referral center between 2018 and 2022, comparing outcomes between the IOCS (n=53) and non-IOCS (n=49) groups, while utilizing inverse probability weighting to address potential selection bias. RESULTS: The analysis revealed that although the IOCS group experienced significantly greater median blood loss (2500 mL versus 1200 mL, p<0.0001), they required fewer allogeneic red blood cell transfusions (2 units versus 1 unit, p<0.0001) without experiencing severe complications such as amniotic fluid embolism. Weak but statistically significant correlations were observed between autologous blood recovery volume and PAS ultrasound scores (r=0.29, p=0.034), whereas total transfusion requirements showed a strong correlation with bleeding severity (r=0.81, p<0.0001). High-risk patients with ultrasound scores ≥9 yielded greater volumes of salvaged blood (715.0 mL vs.484.5 mL, p=0.093) than lower-risk patients. Multivariate regression analysis identified both elevated PAS scores (adjusted OR 1.44, 95% CI 1.06-1.95, p=0.020) and MRI-detected placental vascular abnormalities (adjusted OR 11.11, 95% CI 3.18-38.78, p=0.0002) as independent predictors of transfusion requirements. Comparative analyses showed equivalent hysterectomy rates (16.98% vs.10.20%, p=0.32) and neonatal outcomes, including birth weight (p=0.81), between the two groups. CONCLUSION: These findings demonstrate that IOCS safely decreases dependence on allogeneic blood products in PAS management, particularly benefiting high-risk patients with vascular anomalies or severe imaging scores, while integrating effectively within comprehensive perioperative care protocols. This technology is particularly valuable in well-resourced clinical environments; however, multicenter prospective studies are warranted to standardize the implementation protocols and fully evaluate the cost-benefit ratios across diverse healthcare settings.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。